Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

NCT06379087 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Anlotinib Hydrochloride Capsule
DRUG: Tislelizumab Injection
RADIATION: Hypofractionated Radiotherapy

Sponsor

Ji Yongling